GT Biopharma, Inc. — Director's Dealing 2021

Oct 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GT Biopharma, Inc. (GTBP)
CIK: 0000109657
Period of Report: 2020-11-16

Reporting Person: Wendel Bruce (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-16	Common Stock	P	3268	$3.14	Acquired	3268	Direct
2020-12-22	Common Stock	P	1374	$8.87	Acquired	4642	Direct
2020-12-22	Common Stock	P	441	$8.73	Acquired	5083	Direct
2021-02-16	Common Stock	A	347572	$0.00	Acquired	352655	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-16	Option to purchase Common Stock	$6.33	A	50000	Acquired	2031-02-15	Common Stock (50000)	Direct

Footnotes

F1: Represents a grant of shares of restricted stock ("RSAs"). 1/3rd of the RSAs vest on November 11 2020, 2021 and 2022.

F2: 1/3rd of the shares vest on February 16, 2021, 2022, and 2023.